Cardiometabolic Medicine
The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia. These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
ATTR-CM Second Quarter ’26 Pubs Update: Evolving Evidence, Disease Progression, and the Role of TTR Stabilization in the DMT Era
Update on TTR Stabilizers in ATTR-CM: New Data from ACC 2026
2) Ahmad Masri MD @MasriAhmadMD from @OHSUCardio and Martha Grogan MD @MarthaGrogan1 #cardiologist at #MayoClinic provided a similar summary after...
Does nasal etripamil for PSVT drop blood pressure?
2) This program is intended for #HCPs. Supported by an independent educational grant from Milestone Pharma, it is accredited 🇺🇸🇨🇦🇬🇧🇪🇺. By following...
ATTR-CM : Updated epidemiology, diagnosis, sex disparities and latest TTR stabilizer data from 2026 so far!
2a) This program is intended for #HCPs and is supported by an independent grant from BridgeBio. You can earn a full 1 hr of 🆓CE/#CME credit by...
The (Busy!) Year in Review: The Emergence of Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension in 2025
2) During 2025 you learned about these developments from @PamTaubMD & @edgarvlermamd 🇵🇭. You can still earn 🆓credit at https://t.co/36ZYdDsq8G....
Late-Breaking Clinical Trial Data from AHA 2025 on Approved and Emerging Lipid-Lowering Therapies: Highlights Selected by the Experts
2) The #LBCTs excerpted here were selected by 3⃣international experts on #LLT: Alan Brown MD MHA FACC FNLA @alanbrownmd, Peter P Toth MD PhD FCCP...
Update from AHA2025 on Management of ATTR-CM With TTR Stabilizers and Other Strategies
2) We have other programs on amyloidosis still available for 🆓credit at https://t.co/41keu1YH9J; this is currently a very HOT 🔥area with both more...
Update from AHA2025: New Data on Disease Modifying Therapy in the Management of ATTR Amyloidosis
2a) Our returning expert author is @Ron_Witteles, Professor of Cardiovascular Medicine & @StanfordMedRes IM program director, specialist in...
Patient Self-Management of Acute PSVT: A Systematic Review of Etripamil Data from AHA25
2) .@heartdrsingh is faculty at both @MCG_AUG and College of Health Professions, Mercer University Atlanta. He is Director, Clinical Research at NSC...
The Nephrology Community’s Reception of New Phase 3 Data on Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension at ESC2025
2) You've already seen those data w/@PamTaubMD & u can still earn 🆓credit by checking out https://t.co/Jnm3I9eari. Now we take a look at...
@Cardiomet_CE on Twitter
Your only source for ACCREDITED SoMe-delivered
serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @cardiomet_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.